Exploration of the anti-enterovirus activity of a series of pleconaril/pirodavir-like compounds

Antiviral Chemistry and Chemotherapy

Volumn 24, Issue 2, 2015, Pages 56-61

  Bernard, Angela ^a   Lacroix, Céline ^b   Cabiddu, Maria G ^a   Neyts, Johan ^b   Leyssen, Pieter ^b   Pompei, Raffaello ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Antivirals; Early stage; Enterovirus; Pirodavir; Pleconaril

Indexed keywords

ANTIVIRUS AGENT; PIRODAVIR; PLECONARIL; OXADIAZOLE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDAZINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL PROTECTION; COXSACKIEVIRUS B3; DRUG POTENCY; DRUG SELECTIVITY; EC50; ECHOVIRUS E11; ENTEROVIRUS; ENTEROVIRUS 71; HUMAN; HUMAN CELL; HUMAN POLIOVIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA CELL; VERO CELL LINE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROVIRUS; MICROBIAL SENSITIVITY TESTS; OXADIAZOLES; PIPERIDINES; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84963864883     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/2040206615589035     Document Type: Article

References (18)

1. Palacios G and Oberste MS. Enteroviruses as agents of emerging infectious diseases. J Neurovirol 2005; 11: 424-433.
2. Peltola V, Waris M, Osterback R, et al. Clinical effects of rhinovirus infections. J Clin Virol 2008; 43: 411-414.
3. Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10: 778-790.
4. Liu W, Wu S, Xiong Y, et al. Co-circulation and genomic recombination of coxsackievirus A16 and enterovirus 71 during a large outbreak of hand, foot, and mouth disease in Central China. PLoS One 2014; 9: e96051.
5. Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med 2011; 183: 734-742.
6. Jackson DJ and Johnston SL. The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol 2010; 125: 1178-1187.
7. Andries K, Dewindt B, Snoeks J, et al. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother 1992; 36: 100-107.
8. Florea NR, Maglio D and Nicolau DP. Pleconaril, a novel antipicornaviral agent. Pharmacotherapy 2003; 23: 339-348.
9. Hayden FG, Herrington DT, Coats TL, et al. Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis 2003; 36: 1523-1532.
10. Senior K. FDA panel rejects common cold treatment. Lancet Infect Dis 2002; 2: 264.
11. Hayden FG, Andries K and Janssen PA. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother 1992; 36: 727-732.
12. Hayden FG, Hipskind GJ, Woerner DH, et al. Intranasal pirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother 1995; 39: 290-294.
13. Tucker S. The discovery and development of vapendavir: a potent and selective antiviral with potential for the treatment of picornavirus associated diseases. In: Europic 2014, 18th international Picornavirus meeting, 9-14 March 2014, Blonkenberge, Belgium.
14. Bernard AM, Cabiddu MG, Demontis MS, et al. Synthesis of new compounds with promising antiviral properties against group A and B Human Rhinoviruses. Bioorg Med Chem 2014; 22: 4061-4066.
15. Laconi S, Madeddu MA and Pompei R. Study of the biological activity of novel synthetic compounds with antiviral properties against human rhinoviruses. Molecules 2011; 16: 3479-3487.
16. McGoldrick A, Macadam AJ, Dunn G, et al. Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol 1995; 69: 7601-7605.
17. Wessels E, Duijsings D, Notebaart RA, et al. A prolinerich region in the Coxsackievirus 3A protein is required for the protein to inhibit endoplasmic reticulum-to-golgi transport. J Virol 2005; 79: 5163-5173.
18. Bergelson JM and Coyne CB. Picornavirus entry. Adv Exp Med Biol 2013; 790: 24-41.